文献速递神经肿瘤

2型神经纤维瘤病相关脑膜瘤的初次与挽救性放射外科治疗

Primary and salvage radiosurgery for neurofibromatosis type 2-associated meningiomas.
PubMed 文献 · J Neurosurg · 2024-11-22

该单中心回顾性病例系列纳入1987至2022年接受立体定向放射外科治疗的45例2型神经纤维瘤病相关脑膜瘤患者(共213个肿瘤),中位边缘剂量13 Gy。肿瘤局部控制率5年、10年、15年分别为90.21%、84.46%、84.46%,初次与挽救性放射外科的长期局部控制无显著差异;近半数患者因新发脑膜瘤需再次放射外科治疗。

要点

  • 2型神经纤维瘤病相关脑膜瘤放射外科治疗后5年、10年、15年肿瘤局部控制率分别为90.21%、84.46%、84.46%。
  • 初次与挽救性放射外科的长期局部控制无显著差异。
  • 初始放射外科后44%患者出现新发未治疗脑膜瘤,肿瘤数目多者新发风险更高。

核心结论

  • 在该病例系列中,初次和挽救性放射外科的局部控制率均超过90%,但近半数患者因新发未治疗脑膜瘤需再次放射外科治疗。
  • 初次与挽救性放射外科治疗2型神经纤维瘤病脑膜瘤的长期局部控制无显著差异。
  • 作者认为这些结果确立了放射外科作为2型神经纤维瘤病相关脑膜瘤有价值且安全的选择。

研究设计与样本

  • 单中心回顾性研究,纳入1987年至2022年间接受立体定向放射外科治疗的45例患者(20例男性,213个肿瘤),中位年龄53.5岁(范围20-79岁)。
  • 中位卡氏功能状态评分80分(范围50-100),27例既往接受过切除术,8例既往接受过分次放射治疗。
  • 中位Ki-67增殖指数(n=8)为11.5%(范围9%-27.5%),中位边缘剂量13 Gy(范围9-16 Gy)。
  • 每例患者中位脑膜瘤数目3个(范围1-17个),每例患者中位累计治疗肿瘤体积6.29 cm³(范围0.10-37.70 cm³)。

主要发现

  • 按肿瘤计算的5年、10年、15年局部肿瘤控制率分别为90.21%、84.46%、84.46%。
  • 多因素分析中,较低肿瘤体积与更好的局部肿瘤控制相关(p=0.02;HR 1.07,95%CI 1.01-1.12)。
  • 初始放射外科后,20例(44%)患者出现既往未治疗的新发脑膜瘤;放射外科时脑膜瘤数目较多的患者新发脑膜瘤发生率更高(p=0.01;HR 1.19,95%CI 1.04-1.37)。
  • 随访期间18例患者死亡,其中5例死亡与一个或多个颅内2型神经纤维瘤病相关肿瘤进展有关。
  • 2例(4.44%)患者出现一过性放射不良反应,无患者发生第二恶性肿瘤;8例因局部肿瘤进展需额外放射外科治疗,20例因新发肿瘤接受放射外科治疗,4例对放射外科治疗过的脑膜瘤行延迟切除术。

关键数值与推荐

  • 中位边缘剂量为13 Gy(范围9-16 Gy)。
  • 按肿瘤计算的局部肿瘤控制率:5年90.21%,10年84.46%,15年84.46%。
  • 较低肿瘤体积与更好局部肿瘤控制相关(p=0.02;HR 1.07,95%CI 1.01-1.12)。
  • 放射外科时脑膜瘤数目较多与新发脑膜瘤发生率更高相关(p=0.01;HR 1.19,95%CI 1.04-1.37)。

临床怎么用

  • 原文结论认为放射外科是处理2型神经纤维瘤病相关脑膜瘤有价值且安全的选择。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal management of neurofibromatosis type 2 (NF2)-associated meningiomas must be personalized case by case. Stereotactic radiosurgery (SRS) is one option for patients with one or multiple intracranial meningiomas associated with the NF2 mutation. In this study, the authors evaluated their single-institution experience of SRS treatment for NF2-associated meningiomas. METHODS: The medical records and radiographic images of 45 patients (20 males, 213 tumors) with a median age of 53.5 (range 20-79) years who underwent SRS between 1987 and 2022 were retrospectively reviewed. The median Karnofsky Performance Status score was 80 (range 50-100). Twenty-seven patients had undergone prior resection, and 8 had undergone prior fractionated radiation therapy. The median Ki-67 proliferation index (n = 8) was 11.5% (range 9%-27.5%). The median margin dose was 13 (range 9-16) Gy. The median number of meningiomas per patient was 3 (range 1-17), and the median cumulative tumor volume treated per patient was 6.29 (range 0.10-37.70) cm3. RESULTS: The 5-, 10-, and 15-year local tumor control (LTC) rates per tumor were 90.21%, 84.46%, and 84.46%, respectively. On multivariate analysis, a lower tumor volume was associated with better LTC (p = 0.02; HR 1.07, 95% CI 1.01-1.12). After the initial SRS, 20 (44%) patients developed a previously untreated meningioma. Patients with more meningiomas at the time of SRS had a higher rate of new meningioma development (p = 0.01; HR 1.19, 95% CI 1.04-1.37). Eighteen patients died during the follow-up interval, of which 5 deaths were related to the progression of one or more intracranial NF2-related tumors. Two (4.44%) patients developed transient adverse radiation effects. No patient developed a secondary malignancy. Eight patients required additional SRS for local tumor progression, 20 underwent SRS for new tumor development, and 4 patients underwent delayed resection of an SRS-treated meningioma. CONCLUSIONS: In this case series, the LTC rates of both primary and salvage SRS exceeded 90%. However, nearly half of the patients required additional SRS for new untreated meningiomas. No significant differences in long-term LTC were found when comparing upfront versus salvage SRS for patients with NF2 meningiomas. These results establish SRS as a valuable and safe option for managing NF2-associated meningiomas.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Wei Z, Taori S, Mehta M, et al. Primary and salvage radiosurgery for neurofibromatosis type 2-associated meningiomas. J Neurosurg. 2024. PMID: 39576970. doi:10.3171/2024.7.JNS231815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。